Menopause and HRT

Physiologic (age-related) cause

• Ovarian follicular atresia: The oocyte pool declines from birth onward; once the antral follicle reserve is exhausted, granulosa cell inhibin B and estradiol production fail, FSH rises, and menses cease. This is the mechanism in >90% of cases, with a US median age near 51 years.

Iatrogenic (induced) menopause

• Bilateral oophorectomy: Abrupt, complete loss of ovarian estrogen and androgen — symptoms are more sudden and severe than natural menopause, and bone loss is accelerated.
• Gonadotoxic chemotherapy: Alkylating agents (cyclophosphamide) destroy primordial follicles; risk rises with cumulative dose and patient age.
• Pelvic radiation and, less commonly, hysterectomy with ovarian conservation, which can compromise ovarian blood supply and advance menopause by a few years.

Primary ovarian insufficiency (menopause before age 40)

• Genetic: Turner syndrome (45,X) with streak gonads; FMR1 premutation (fragile X carriers) — the single association examiners most often test, since it warrants family genetic counseling.
• Autoimmune: Autoimmune oophoritis, frequently with autoimmune polyglandular syndrome and adrenal insufficiency; check adrenal and thyroid autoimmunity.
• Metabolic: Classic galactosemia.

Non-modifiable risk factors for earlier menopause

• Family history/genetics (strongest predictor of age at menopause), nulliparity, and prior pelvic surgery or autoimmune disease.

Modifiable risk factors

• Cigarette smoking: Anti-estrogenic effect and direct follicular toxicity; consistently advances menopause by roughly 1–2 years and worsens vasomotor symptoms.
• Low body weight/undernutrition, and conversely obesity, which is associated with more bothersome hot flushes despite higher peripheral aromatization of androgens to estrone in adipose tissue.

• Follicle depletion and FSH elevation: Declining numbers of ovarian follicles reduce inhibin production, leading to loss of negative feedback on the anterior pituitary. Consequently, FSH levels rise dramatically (>30 mIU/mL), while LH also increases. This hormonal shift occurs during perimenopause (4-10 years prior to final menses) when cycles become irregular.

• Estrogen deficiency and receptor downregulation: The decline in ovarian 17β-estradiol production results in systemic estrogen deficiency. Estrogen receptors (ER-α and ER-β) are widely distributed in the hypothalamus, blood vessels, bone, genitourinary tract, and brain. Loss of estrogen signaling disrupts thermoregulation (causing hot flushes), impairs vasomotor stability, and reduces collagen synthesis in vaginal tissue.

• Vasomotor instability: Estrogen regulates serotonin, norepinephrine, and dopamine pathways in the hypothalamus. Estrogen deficiency increases noradrenergic tone and serotonergic dysfunction, narrowing the thermoneutral zone and triggering sudden cutaneous vasodilation and perspiration (hot flushes and night sweats).

• Bone loss acceleration: Estrogen suppresses osteoclast activity and promotes osteoblast apoptosis resistance. Estrogen deficiency leads to increased osteoclastic bone resorption (10-20% bone loss in first 5-8 years post-menopause), with particular vulnerability at the hip, spine, and wrist—increasing fracture risk.

• Genitourinary atrophy: Decreased estrogen causes thinning of the vaginal epithelium, reduced glycogen content, alterations in vaginal microbiota, and diminished vaginal blood flow. This leads to vaginal dryness, reduced elasticity, and recurrent urinary tract infections.

• Cardiovascular changes: Estrogen loss removes cardioprotective effects (improved lipid profiles, endothelial function, and vasodilation). Menopause is associated with increased LDL, decreased HDL, increased triglycerides, and heightened inflammation, accelerating atherosclerosis risk.

• Vasomotor symptoms (hot flushes and night sweats): Sudden onset of facial flushing, chest flushing, and profuse diaphoresis lasting 2-30 minutes; occur 8-10 times daily on average. Night sweats disrupt sleep and can be severe enough to require clothing changes. Affect 60-80% of menopausal women and typically persist 4-9 years (some experience them for 10+ years).

• Mood and cognitive symptoms: Depression, anxiety, irritability, brain fog, and difficulty with concentration or memory. These may relate to hormonal changes, sleep disruption from night sweats, or independent neurobiological effects of estrogen deficiency. Some women experience emotional lability or panic attacks.

• Genitourinary symptoms: Vaginal dryness, dyspareunia (painful intercourse), vaginal itching, and urinary urgency or dysuria from urethral and bladder atrophy. Recurrent urinary tract infections are common. Stress urinary incontinence may worsen.

• Sleep disturbance: Insomnia and poor sleep quality driven primarily by night sweats but also by mood changes. Sleep deprivation compounds fatigue, mood symptoms, and cognitive dysfunction.

• Musculoskeletal symptoms: Arthralgias (joint aches), myalgias, and stiffness—sometimes termed "menopausal arthralgia"—that may be hormonally mediated. These symptoms are often underrecognized.

• Skin and hair changes: Decreased skin elasticity and collagen content cause wrinkles and dryness. Vaginal and pubic hair may thin or lose pigmentation. Scalp hair thinning or increased facial hair growth may occur.

• Important clinical pearls: Symptom severity is not correlated with estrogen levels—it is individual and unpredictable. Symptoms may onset during perimenopause before the final menstrual period. The FSH-dependent vasomotor flush is highly specific for menopause and responds best to HRT.

• Clinical diagnosis based on history: Diagnosis of menopause is made clinically in women >40 years with amenorrhea for 12 consecutive months and typical menopausal symptoms. Laboratory confirmation is not routinely needed in this population, as clinical presentation is highly reliable.

• FSH and estradiol testing: Reserved for younger women (<40 years) with menopausal symptoms or those with ambiguous presentations. FSH >30 mIU/mL (using follicular phase standards) and low estradiol (<30 pg/mL) support menopause diagnosis. FSH can be elevated during perimenopause but estradiol remains in reproductive range due to cycle variability.

• Perimenopause diagnosis: Characterized by irregular menses and elevated FSH despite ongoing ovulation. Diagnosis is clinical—irregular cycle length >7 days different from baseline over ≥2 cycles, combined with menopausal symptoms. FSH testing is less reliable during perimenopause due to fluctuations.

• Important diagnostic considerations: Rule out other causes of amenorrhea or hot flushes (pregnancy, thyroid disease, tuberculosis, lymphoma). Thyroid-stimulating hormone (TSH) should be checked if symptoms are atypical. Pregnancy tests should be performed in perimenopausal women using contraception, as pregnancy can occur. Bone density screening (DEXA scan) should be considered at baseline for all postmenopausal women or those on long-term HRT to assess fracture risk.

First-line treatment for moderate-to-severe vasomotor symptoms

• Estrogen-progestin HRT (combined HRT): Standard regimen for women with intact uterus. Oral conjugated estrogens 0.625 mg daily or 17β-estradiol 1-2 mg daily, combined with medroxyprogesterone acetate (MPA) 2.5-5 mg daily or micronized progesterone 100-200 mg daily. Transdermal estradiol patches (0.05-0.1 mg/day) are preferred in some patients due to lower thrombotic risk and more physiologic absorption. Effective in 80-90% of women for vasomotor symptom relief within 1-4 weeks.

• Estrogen-only HRT (unopposed estrogen): Reserved exclusively for hysterectomized women to avoid endometrial hyperplasia. Typical regimens include conjugated estrogens 0.625 mg daily or transdermal estradiol 0.05-0.1 mg/day.

• Dosing and duration: Start at the lowest effective dose; many women respond to lower doses (e.g., 0.3 mg conjugated estrogens). Reassess symptoms after 3 months and titrate as needed. Consider discontinuation or tapering every 1-2 years; many women experience natural symptom resolution, though some require longer-term use.

Second-line and alternative treatments

• Selective serotonin reuptake inhibitors (SSRIs): Paroxetine (7.5 mg XR daily, FDA-approved for hot flushes), sertraline (50-100 mg daily), or venlafaxine (ER 75 mg daily) reduce hot flushes by 25-60%. Effective for mood symptoms and can be first-line if HRT is contraindicated. Onset of benefit within 1-2 weeks.

• Serotonin-norepinephrine reuptake inhibitors (SNRIs): Venlafaxine (75-150 mg daily) and desvenlafaxine (100 mg daily) show efficacy similar to SSRIs

Complications of estrogen deficiency

• Osteoporosis and fragility fracture: Unopposed osteoclastic resorption (loss of estrogen-mediated RANKL suppression) produces rapid trabecular loss. Signaled by height loss, kyphosis, a vertebral compression fracture on imaging, or T-score ≤ −2.5 on DEXA. USPSTF recommends DEXA screening in all women at 65, earlier if FRAX risk is equivalent. Hip fracture carries substantial one-year mortality — the most consequential downstream event.
• Atherosclerotic cardiovascular disease: Loss of favorable lipid and endothelial effects raises LDL and shifts risk upward after menopause; ACC/AHA primary prevention guidance treats premature menopause (<40) and adverse pregnancy history as risk-enhancing factors favoring statin therapy in borderline/intermediate risk.
• Genitourinary syndrome of menopause: Epithelial thinning and loss of glycogen shift vaginal pH upward and permit uropathogen colonization — recurrent UTIs, dyspareunia, and vaginal bleeding from atrophy. Progressive and does not remit spontaneously.

Complications of hormone therapy

• Endometrial hyperplasia and carcinoma: Caused by unopposed estrogen mitogenic stimulation in a woman with a uterus. Any postmenopausal bleeding is endometrial cancer until proven otherwise — obtain transvaginal ultrasound and/or endometrial biopsy; do not attribute it to "breakthrough bleeding."
• Venous thromboembolism: Oral estrogen undergoes first-pass hepatic metabolism and increases procoagulant factor synthesis. Acute dyspnea, pleuritic pain, and hypoxemia signal PE — an emergency. Transdermal estradiol bypasses first pass and carries lower thrombotic risk.
• Ischemic stroke and coronary events: Increased in the Women's Health Initiative when therapy was begun remote from menopause or after age 60. Sudden focal deficit is a stroke emergency — activate stroke protocol.
• Breast cancer: Increased with combined estrogen–progestin after several years of use in WHI; estrogen-alone in hysterectomized women did not show this increase. Signaled by a new palpable mass or abnormal mammogram.
• Gallbladder disease from increased biliary cholesterol saturation with oral estrogen.
• Drug interaction: Paroxetine and fluoxetine inhibit CYP2D6 and reduce tamoxifen activation — use venlafaxine instead in breast cancer survivors.

• Menopause is a clinical, retrospective diagnosis: 12 months of amenorrhea in a woman over 45 with typical symptoms. Ordering FSH in that patient is the classic wrong answer — reserve testing for suspected primary ovarian insufficiency under age 40.

• Postmenopausal bleeding is the single best-next-step question: the answer is endometrial evaluation (transvaginal ultrasound with endometrial stripe measurement and/or endometrial biopsy), never reassurance and never simply adjusting the HRT dose.

• Uterus present means progestin required: unopposed estrogen causes endometrial hyperplasia and carcinoma. Estrogen-alone is correct only after hysterectomy. This pairing is tested more than any other HRT fact.

• The timing hypothesis: The Menopause Society (NAMS) 2022 position statement supports systemic HRT when initiated before age 60 or within 10 years of the final menstrual period in symptomatic women without contraindications; the risk–benefit ratio worsens with later initiation.

• HRT is not for prevention: USPSTF recommends against menopausal hormone therapy for the primary prevention of chronic conditions such as cardiovascular disease or dementia. A stem offering "start HRT to prevent osteoporosis" in an asymptomatic woman is a distractor — bisphosphonates are the answer for established osteoporosis.

• Isolated genitourinary syndrome gets low-dose vaginal estrogen, which has minimal systemic absorption and does not require added progestin — do not escalate to systemic therapy for dryness and dyspareunia alone.

• Absolute contraindications to systemic estrogen: history of breast or other estrogen-dependent cancer, prior VTE or stroke, coronary disease, active liver disease, and undiagnosed vaginal bleeding. For these patients, non-hormonal options include SSRI/SNRIs and the neurokinin-3 receptor antagonist fezolinetant; avoid paroxetine with tamoxifen (CYP2D6 inhibition).

• Contraception still applies in perimenopause: ovulation is erratic but possible, so contraception is continued until 12 months of amenorrhea. Hot flushes plus a positive pregnancy test is a favorite trap.